{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T23:19:35Z","timestamp":1792279175471,"version":"4.4.0"},"reference-count":32,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":14,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["UEG Journal"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>LIBERTY\u2010CD and LIBERTY\u2010UC demonstrated superior efficacy of subcutaneous infliximab (IFX SC) to placebo in patients with Crohn's disease (CD) or ulcerative colitis (UC). Here, we investigated the impact of anti\u2010drug antibodies (ADAs) on clinical outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Patients randomized to IFX SC maintenance treatment in the LIBERTY trials were included (CD,\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a0231; UC,\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a0294). ADAs were tested using a highly sensitive, drug\u2010tolerant assay. Patients were grouped by ADA occurrence and titer and evaluated for outcomes up to Week (W) 54.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among patients with CD and UC, 150 (64.9%) and 187 (63.6%) were ADA\u2010positive, respectively. No statistically significant differences were observed between the ADA\u2010positive and ADA\u2010negative groups in W54 efficacy (CD: clinical remission, 69.5% [95% confidence interval: 61.6\u201377.5] vs. 79.7% [70.2\u201389.2],\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.134; endoscopic response, 57.5% [48.9\u201366.1] vs. 65.2% [54.0\u201376.5],\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.359; UC: clinical remission, 49.1% [41.3\u201356.8] vs. 57.0% [46.5\u201367.4],\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.284), drug persistence (CD: 84.7% [79.1\u201390.6] vs. 85.2% [77.8\u201393.3]; UC: 84.5% [79.5\u201389.8] vs. 77.6% [70.1\u201385.9]), and safety (patients with \u2265 1 treatment\u2010emergent adverse event; CD: 71.2% [64.0\u201378.3] vs. 74.4% [64.9\u201383.8]; UC: 69.5% [62.9\u201376.0] vs. 64.2% [55.0\u201373.3]), despite lower drug concentrations in ADA\u2010positive patients at W54 (CD: 10.6\u00a0\u03bcg\/mL [9.1\u201312.2] vs. 17.9\u00a0\u03bcg\/mL [15.8\u201320.1]; UC: 12.2\u00a0\u03bcg\/mL [10.8\u201313.5] vs. 21.0\u00a0\u03bcg\/mL [18.4\u201323.6]). No significant relationship between ADA titer and efficacy or persistence was noted.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Although ADAs affected drug levels, no significant differences by ADA occurrence were observed in W54 efficacy or safety among patients receiving IFX SC maintenance treatment. While high ADA titers were associated with lower drug levels, effectiveness was not diminished within 1\u00a0year.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>ClinicalTrials.gov identifiers NCT03945019 (LIBERTY\u2010CD) and NCT04205643 (LIBERTY\u2010UC)<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ueg2.70205","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T01:46:28Z","timestamp":1776303988000},"source":"Crossref","is-referenced-by-count":3,"title":["Impact of Immunogenicity on Clinical Outcomes in Patients With Moderate\u2010to\u2010Severe Inflammatory Bowel Disease Receiving Subcutaneous Infliximab: A Post Hoc Analysis of the LIBERTY Trials"],"prefix":"10.1002","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6472-249X","authenticated-orcid":false,"given":"Jean\u2010Fr\u00e9d\u00e9ric","family":"Colombel","sequence":"first","affiliation":[{"name":"Dr. Henry D. Janowitz Division of Gastroenterology Icahn School of Medicine at Mount Sinai  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7341-1351","authenticated-orcid":false,"given":"Silvio","family":"Danese","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology IRCCS San Raffaele Hospital and Vita\u2010Salute University  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6807-9822","authenticated-orcid":false,"given":"Stefan","family":"Schreiber","sequence":"additional","affiliation":[{"name":"Department of Medicine I University Hospital Schleswig\u2010Holstein Kiel University  Kiel Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5762-5042","authenticated-orcid":false,"given":"Bruce E.","family":"Sands","sequence":"additional","affiliation":[{"name":"Dr. Henry D. Janowitz Division of Gastroenterology Icahn School of Medicine at Mount Sinai  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2293-5555","authenticated-orcid":false,"given":"Andres J.","family":"Yarur","sequence":"additional","affiliation":[{"name":"F. Widjaja Inflammatory Bowel Disease Institute Cedars Sinai Medical Center  Los Angeles California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4012-6752","authenticated-orcid":false,"given":"Aram","family":"Kang","sequence":"additional","affiliation":[{"name":"Global Medical Division Celltrion Inc.  Incheon Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0585-2432","authenticated-orcid":false,"given":"Dong\u2010Hyeon","family":"Kim","sequence":"additional","affiliation":[{"name":"Global Medical Division Celltrion Inc.  Incheon Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2776-4708","authenticated-orcid":false,"given":"Young Nam","family":"Lee","sequence":"additional","affiliation":[{"name":"Global Medical Division Celltrion Inc.  Incheon Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3268-932X","authenticated-orcid":false,"given":"Stephen B.","family":"Hanauer","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine Feinberg School of Medicine Northwestern University  Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"key":"e_1_2_14_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.103017"},{"key":"e_1_2_14_3_1","doi-asserted-by":"publisher","DOI":"10.1177\/17562848211059954"},{"key":"e_1_2_14_4_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2021.04.022"},{"key":"e_1_2_14_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco\u2010jcc\/jjab178"},{"key":"e_1_2_14_6_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248\u2010025\u201001118\u20106"},{"key":"e_1_2_14_7_1","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/3072586"},{"key":"e_1_2_14_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2012.363"},{"key":"e_1_2_14_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/s2468\u20101253(19)30012\u20103"},{"key":"e_1_2_14_10_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01951"},{"key":"e_1_2_14_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020888"},{"key":"e_1_2_14_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2015.10.029"},{"key":"e_1_2_14_13_1","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2003.50145"},{"key":"e_1_2_14_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2017.04.002"},{"key":"e_1_2_14_15_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756283x17750355"},{"key":"e_1_2_14_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(02)08512\u20104"},{"key":"e_1_2_14_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474124.2024.2409300"},{"key":"e_1_2_14_18_1","unstructured":"European Medicines Agency. \u201cRemsima Summary of Product Characteristics \u201d\u00a02023. Accessed March 6 2025 https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/remsima\u2010epar\u2010product\u2010information_en.pdf."},{"key":"e_1_2_14_19_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2021.02.068"},{"key":"e_1_2_14_20_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2024.05.006"},{"key":"e_1_2_14_21_1","unstructured":"US Food and Drug Administration. \u201cZymfentra: Highlights of Prescribing Information \u201d2023. Accessed March 6 2025 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761358s000lbl.pdf."},{"key":"e_1_2_14_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco\u2010jcc\/jjae059"},{"key":"e_1_2_14_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.70267"},{"key":"e_1_2_14_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325\u2010021\u201001990\u20106"},{"key":"e_1_2_14_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261\u2010022\u201001162\u20106"},{"key":"e_1_2_14_26_1","unstructured":"European Medicines Agency. \u201cGuideline on Immunogenicity Assessment of Therapeutic Proteins \u201d2017. Accessed August 29 2025 https:\/\/www.ema.europa.eu\/en\/documents\/scientific\u2010guideline\/guideline\u2010immunogenicity\u2010assessment\u2010therapeutic\u2010proteins\u2010revision\u20101_en.pdf."},{"key":"e_1_2_14_27_1","unstructured":"US Food and Drug Administration. \u201cImmunogenicity Testing of Therapeutic Protein Products \u2014 Developing and Validating Assays for Anti\u2010Drug Antibody Detection \u201d2019. Accessed August 29 2025 https:\/\/www.fda.gov\/media\/119788\/download."},{"key":"e_1_2_14_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2012.06.002"},{"key":"e_1_2_14_29_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248\u2010016\u20109981\u20103"},{"key":"e_1_2_14_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izaf038"},{"key":"e_1_2_14_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/mib.0000000000001043"},{"key":"e_1_2_14_32_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11206173"},{"key":"e_1_2_14_33_1","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000003466"}],"container-title":["United European Gastroenterology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ueg2.70205","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ueg2.70205","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ueg2.70205","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T08:03:26Z","timestamp":1780733006000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ueg2.70205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1002\/ueg2.70205"],"URL":"https:\/\/doi.org\/10.1002\/ueg2.70205","archive":["Portico"],"relation":{},"ISSN":["2050-6406","2050-6414"],"issn-type":[{"value":"2050-6406","type":"print"},{"value":"2050-6414","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]},"article-number":"e70205"}}